pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.
Tour Hekla
Tour Hekla is a pharma organization headquartered in EU. Primary therapeutic focus areas include Muscle-invasive bladder cancer (MIBC), Acute ischaemic stroke due to basilar artery occlusion., Thrombotic episodes in supe
Puteaux, Ile de France 92800, FR HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Puteaux, Ile de France 92800, FR
- Employees
- 6
- Programs
- 27
- Drugs
- 71
- Patents
- 0
Tecentriq 1 200 mg concentrate for solution for infusion
Phase 2 · small molecule · Muscle-invasive bladder cancer
Tecentriq 1 200 mg concentrate for solution for infusion for Muscle-invasive bladder cancer is a Phase 2 program (small_molecule) at Tour Hekla with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tour Hekla
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Muscle-invasive bladder cancer
- Status
- active
- Trials
- 1